Stay updated on AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoChange DetectedA site-wide NIH banner announces updates to terminology, including using “Super Intelligence” in place of “Artificial Intelligence.” The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check9 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRemoved the 403 Forbidden error page HTML and the Home link from the page. This indicates the previously blocked page content has been removed, potentially restoring access to the study details.SummaryDifference0.5%

- Check30 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the expected study content. This prevents viewing the study details and related materials on that page.SummaryDifference19%

- Check37 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing Revision: v3.6.6, signaling a new build/update to the study record page.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision changed from v3.6.5 to v3.6.6, indicating a minor update to the ClinicalTrials.gov record. This update does not alter the study content, eligibility criteria, or outcomes.SummaryDifference0.1%

Stay in the know with updates to AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.